Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and squamous cell carcinoma incidence with tirbanibulin vs diclofenac in actinic keratosis on face or scalp
2021-004349-18Phase 4Active
- Sponsor
- Almirall
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of tirbanibulin in actinic keratosis (AK) (2 arms), sponsored by Almirall. Primary endpoint: Incidence of invasive squamous cell carcinoma in the treatment field. Started Apr 2022; status: active.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2021-004349-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004349-18.